Medications for Paroxysmal Hemoglobinuria
8 results
Bkemv (eculizumab-aeeb)
(eculizumab-aeeb)Amgen Inc
Usage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive. Not for Shiga toxin E. coli related HUS.
Empaveli (pegcetacoplan)
(Pegcetacoplan)Apellis Pharmaceuticals, Inc.
Usage: EMPAVELI® is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Epysqli (eculizumab-aagh)
(Eculizumab-aagh)Samsung Bioepis Co., Ltd.
Usage: EPYSQLI is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive. Limitations apply for STEC-HUS.
Fabhalta (iptacopan)
(iptacopan)Novartis Pharmaceuticals Corporation
Usage: FABHALTA is indicated for treating adults with paroxysmal nocturnal hemoglobinuria (PNH), reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid progression, and treating adults with complement 3 glomerulopathy (C3G) to reduce proteinuria.
Piasky (crovalimab)
(Crovalimab)Genentech, Inc.
Usage: PIASKY is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) in adult and pediatric patients aged 13 years and older who weigh at least 40 kg.
Soliris (eculizumab)
(ECULIZUMAB)Alexion Pharmaceuticals Inc
Usage: SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit thrombotic microangiopathy, generalized myasthenia gravis (gMG) in patients aged six and older, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 positive adults.
Ultomiris (ravulizumab)
(ravulizumab)Alexion Pharmaceuticals Inc
Usage: ULTOMIRIS is indicated for treating adult and pediatric patients aged one month and older with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Additionally, it is used for adult patients with generalized myasthenia gravis (anti-AChR antibody-positive) and neuromyelitis optica spectrum disorder (AQP4 antibody-positive).
Voydeya (danicopan)
(Danicopan)Alexion Pharmaceuticals Inc
Usage: VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for treating extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria. It is not effective as a monotherapy and should only be used alongside these medications.